FEDERAL COURT OF AUSTRALIA
Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC [2006] FCA 1353
RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826) v WARNER-LAMBERT COMPANY LLC AND COMMISSIONER OF PATENTS
VID 926 OF 2005YOUNG J
10 OCTOBER 2006
MELBOURNE
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 926 OF 2005
BETWEEN:
RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826)
Applicant / Cross RespondentAND:
WARNER-LAMBERT COMPANY LLC
First Respondent / Cross ClaimantCOMMISSIONER OF PATENTS
Second Respondent
JUDGE:
YOUNG J
DATE:
10 OCTOBER 2006
PLACE:
MELBOURNE
RULING ON EVIDENCE
Warner‑Lambert Company LLC (‘Warner-Lambert’) has objected to the admissibility of passages in three affidavits of Gregory Ralph Tye dated 22 June 2006, 24 July 2006 and 18 September 2006 respectively. After some discussion and some concessions by Ranbaxy Australia Pty Ltd (‘Ranbaxy’), the objections were narrowed to the following paragraphs: paras 4, 6 and 7 of the affidavit of 22 June 2006 (‘the first affidavit’), paras 20 to 28 of the affidavit of 24 July 2006 (‘the second affidavit’), and paras 5 to 7 of the affidavit of 18 September 2006 (‘the third affidavit’).
Mr Tye is a partner at Norman Waterhouse, the solicitors acting for Ranbaxy in these proceedings. In the paragraphs to which objection has been taken, Mr Tye seeks to tender documents that fall into two broad categories. The first category concerns communications between Warner‑Lambert, or its patent attorneys or other agents, and the Danish Patent Directorate and the European Patent Office: see paras 4, 6 and 7 of Mr Tye's first affidavit, paras 20 to 23 and 27 of his second affidavit and paras 5 and 6 of his third affidavit. The nature of these communications is sufficiently indicated by Exhibit GRT3, which is a letter from Warner‑Lambert's patent attorney to the Danish Patent Directorate dated 18 May 1993. That letter responded to certain objections and queries raised by the Danish Patent Office. In the letter, Warner‑Lambert's patent attorney said that to comply with European nomenclature rules concerning stereochemistry, all references to ‘trans’ in the patent application had been changed to ‘trans (±)’. Ranbaxy contends that the symbol (±) indicates that the compound in question is a racemate. The second category comprises communications between Warner-Lambert or its agents and the United States Patent Office concerning the United States enantiomer patent. This category of communications is referred to in Mr Tye's second affidavit at paras 24 to 26.
Ranbaxy argued that these documents are relevant and admissible because they provide part of the context for the construction of Australian Letters Patent No 601981 (‘the Basic Patent’). The equivalent United States patent was filed on 30 May 1986 and all of the communications in question post date that application. Ranbaxy contends that, on its proper construction, the Basic Patent is confined to a racemic mixture and does not claim the individual trans enantiomers. Ranbaxy seeks to rely upon the documents in support of that construction. It contends that the documents provide evidence that, from the…
Keep reading for free
Create a free CaseChat account to read Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2006] FCA 1353
- Decision Date
CaseChat Overview and Summary
The court held that the affidavits and the documents they referred to were inadmissible. It reasoned that the construction of a patent is a legal question and that evidence of the patentee's intentions, whether direct or indirect, is not admissible. This was consistent with established principles in patent law and contract law. The court also referred to relevant precedents from the United Kingdom and Ireland, where similar documents were deemed inadmissible. Additionally, the court exercised its discretion under the Evidence Act 1995 (Cth) to reject the material, finding that its admission would likely result in a waste of court time with little benefit.
In conclusion, the court ruled that the specified paragraphs of the affidavits and the documents they referenced were inadmissible in the case. This ruling underscored the importance of adhering to established legal principles in patent disputes and the limitations on the admissibility of certain types of evidence.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Established by: YOUNG J
Full text does not contain this section.